Occupational asthma due to methyl methacrylate and cyanoacrylates

S LOZEWICZ, AG DAVISON, A HOPKIRK, PS BURGE, DAR BOLDY, JF RIORDAN, DV McGIVERN, BW PLATTS, D DAVIES, AJ NEWMAN TAYLOR

From Brompton Hospital and Central Middlesex Hospital, London; King Edward VII Hospital, Midhurst; East Birmingham Hospital and Dudley Road Hospital, Birmingham; and City Hospital and the Employment Medical Advisory Service, Nottingham

ABSTRACT

Five patients had asthma provoked by cyanoacrylates and one by methyl methacrylate, possibly because of the development of a specific hypersensitivity response. Acrylates have wide domestic as well as industrial uses, and inhalation of vapour emitted during their use can cause asthma.

Acrylates are widely used in the manufacture of adhesives, solvents, acrylic resins, and thermoplastics. Cyanoacrylate based glues give a high bond strength between a variety of materials and are available for domestic use as Superglue and for surgical use as tissue adhesives. Methacrylates, which are chemically distinct from cyanoacrylates, serve as bases for acrylic resins, which have various applications, including use as adhesives and fillers in dental and orthopaedic procedures. Workers in pathology laboratories may be exposed as a result of their use in the plastic embedding of histological specimens.

Low molecular weight acrylic monomers are irritant to the eyes and mucous membranes, and have been reported to produce dermatitis and pulmonary oedema, but there is no previous report of an association with asthma. We report five cases of asthma occurring in association with exposure to cyanoacrylate based adhesives, and one case occurring in relation to exposure to methyl methacrylate. In each case, inhalation testing that mimicked exposure at work provoked an asthmatic reaction.

Methods

In patients 2 and 3 histamine reactivity was measured by a modification of the method of de Vries. Histamine acid phosphate solution was delivered from a Wright nebuliser with an oxygen flow rate of 8 litres per minute. The aerosol was inhaled via a face mask with rebreathing bag for 30 seconds and FEV₁ was measured after five minutes. This was repeated with twofold increases in concentration until a 10% fall in FEV₁ occurred or the maximum concentration of 32 mg/ml of histamine was reached. A fall in FEV₁ of 10% obtained with this method was taken to indicate the presence of bronchial hyperreactivity. In patients 1 and 7 histamine reactivity was measured by the method of Cockcroft et al.

Case reports

Results of bronchial provocation testing are shown in the table.

PATIENT 1
A 52 year old man worked in the manufacture of scientific instruments. About one month after starting to use a methyl cyanoacrylate adhesive, he developed work related respiratory symptoms. He stopped using the adhesive at work and 11 weeks later was admitted to hospital for investigation. Skin prick tests with common inhalant allergens gave negative results. No fall in FEV₁ followed challenge with histamine. Inhalation testing—the patient working with cyanoacrylate glue in the same way as at work for 25 minutes—provoked a 42% fall in FEV₁ 15 hours after the challenge and symptoms of rhinitis during most of the day (fig 1).

PATIENT 2
A 53 year old woman worked as a solderer in an electronics factory for 10 years before the onset of respiratory symptoms. Two weeks after starting to use an ethyl cyanoacrylate adhesive to assemble
Occupational asthma due to methyl methacrylate and cyanoacrylates

Results of bronchial provocation

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Bronchial reactivity to histamine</th>
<th>Acrylate</th>
<th>Asthmatic reaction to acrylate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal</td>
<td>Methyl cyanoacrylate</td>
<td>Non-immediate</td>
</tr>
<tr>
<td>2</td>
<td>Normal</td>
<td>Ethyl cyanoacrylate</td>
<td>Non-immediate</td>
</tr>
<tr>
<td>3</td>
<td>Normal</td>
<td>Alkyl cyanoacrylate</td>
<td>Non-immediate</td>
</tr>
<tr>
<td>4</td>
<td>Not known</td>
<td>Ethyl cyanoacrylate</td>
<td>Dual</td>
</tr>
<tr>
<td>5</td>
<td>Not known</td>
<td>Ethyl cyanoacrylate</td>
<td>Dual</td>
</tr>
<tr>
<td>6</td>
<td>Not known</td>
<td>Methyl methacrylate</td>
<td>Immediate</td>
</tr>
<tr>
<td>7</td>
<td>Normal</td>
<td>Methyl methacrylate</td>
<td>No reaction</td>
</tr>
</tbody>
</table>

Components she began to cough and wheeze. During a week away from work these symptoms improved, but on her return they recurred. She left her job and five months later was admitted for investigation. No fall in FEV<sub>1</sub> followed challenge with histamine. Single blind inhalation testing with cyanoacrylate glue provoked a 21% fall in FEV<sub>1</sub> seven hours after the test. FEV<sub>1</sub> returned to prechallenge levels during the following 48 hours. No asthmatic reaction occurred on a separate control day, when there was no exposure to cyanoacrylate glue (table and figure 1). Skinprick test responses were positive for four common inhalant allergens.

**Patient 4**

A 46 year old woman worked in a factory assembling lampshades for four months without developing respiratory symptoms. Three weeks after starting to use an ethyl cyanoacrylate adhesive she developed episodes of cough and shortness of breath. Her cough became continuous and she began to wheeze, particularly at night. One week after she had stopped being exposed at work single blind inhalation testing with cyanoacrylate glue produced symptoms of rhinitis and an immediate fall in peak expiratory flow (PEF) of 21%. This resolved, but there followed a progressive non-immediate fall, reaching a maximum seven hours after the test of 64% below the pretest value (table). Exposure to a non-cyanoacrylate glue on a control day produced no asthmatic reaction. Skinprick tests with common inhalant allergens gave negative results.

**Patient 5**

A 24 year old woman worked in the same factory as patient 4. Two weeks after starting to use an ethyl cyanoacrylate adhesive she developed symptoms of rhinitis and also nocturnal cough and wheeze that improved at weekends. She changed her occupation at work to avoid further exposure, and two months

![Graph](http://thorax.bmj.com/)

Fig 1 Results of inhalation tests in patients 1 and 2: lung function after exposure to acrylate (see text) (---) and on a control day (---). Treatment with inhaled salbutamol aerosol 200 μg is indicated by an arrow.
later single blind inhalation testing with cyanoacrylate glue provoked an immediate fall in PEF of 28%. This resolved but was followed by a 28% fall at 8 hours (table). Inhalation testing with a non-cyanoacrylate glue on a separate control day produced no asthmatic reaction. Skin prick tests produced positive responses to four common inhalant allergens.

PATIENT 6
A 40 year old dental assistant mixed polymethyl methacrylate powder with monomethyl methacrylate liquid to produce a paste used in the manufacture of dental prosthetic trays. After several years of this work he began to experience chest tightness, dyspnoea, and cough, which persisted for several hours after exposure to even small amounts of methyl methacrylate. He gave no history of wheeze or difficulty breathing other than during the episodes at work, and had never been unduly short of breath on exertion. Two weeks after his last exposure at work he underwent inhalation testing in hospital. He mixed methyl methacrylate monomer and polymer, as at work, for 20 minutes. This provoked a fall in PEF of 24%, which resolved over two hours. The test was repeated one week later and provoked a similar immediate asthmatic reaction. No formal control test was made; but serial measurements of peak flow during the week between the two tests varied by less than 10% around 600 litres per minute, except for a morning dip to 500 litres per minute on waking, which improved spontaneously to 600 litres per minute by 12 midday, the time of the inhalation tests. He has had no recurrence of his asthma during this period.

PATIENT 7
A 52 year old railway cable joiner, who had smoked cigarettes for many years, used an acrylic cold curing resin system containing methyl methacrylate. He developed symptoms of headache, sweating, and lassitude, which occurred in relation to working with the resin system. Although he later developed frequent attacks of cough and wheeze, these respiratory symptoms were not clearly work related. No fall in FEV₁, followed inhalation challenge with histamine but serial recordings of peak expiratory flow rate indicated asthma. No asthmatic reaction followed single blind inhalation testing using the resin or control system (table). Skin prick tests with common inhalant allergens gave negative results.

Discussion
Our findings suggest that in five patients reported here cyanoacrylates are a primary cause of asthma and not acting as a non-specific provocative stimulus in individuals with hyperreactive airways. Each of the five patients who worked with cyanoacrylates had an initial symptom free period of exposure. None of the three tested with histamine showed increased responsiveness before their inhalation tests with cyanoacrylates and these inhalation tests provoked a non-immediate asthmatic reaction in all three. Airway reactivity increases after non-immediate asthmatic reactions and decreases with avoidance of exposure to its inducing cause. Each of these three patients had avoided or reduced their exposure to cyanoacrylates before inhalation testing, which probably explains the absence of increased airway reactivity before the tests. We did not repeat the histamine tests after the inhalation tests with cyanoacrylates, but possibly airway reactivity would have increased after the late asthmatic reactions.

Cyanoacrylate adhesives were introduced for
commercial use in 1958. Methyl cyanoacrylate has been most commonly used but more recently ethyl and butyl types have become available. In general, the higher homologues do not have such good bond strength as the methyl homologue but they have the advantage of being less volatile. Cyanoacrylates readily react with water, polymerising to less volatile polymers. When the relative humidity is high, they react with water vapour in the air and the atmospheric concentration of cyanoacrylate monomer is reduced. Calnan reported an outbreak of irritant dermatitis associated with the use of ethyl cyanoacrylate glue in electronic assembly workers. This was caused by vapourisation of monomer under conditions of low relative humidity; no further outbreak occurred after the humidity of the working environment had been raised above 55%. Serial recordings of peak expiratory flow rate in patient 3 showed that her asthma was less severe when the atmospheric humidity was relatively high (fig 2).

Methyl methacrylate is a clear, flammable liquid that polymerises readily to form non-toxic resins and plastics. It is widely used in surgery as a bone cement and in dentistry as a ceramic filler or cement. It is also used as a medicinal spray adhesive and a non-irritant bandage solvent. Threshold limits for methyl methacrylate of 100 ppm have been recommended. Methyl methacrylate provoked an immediate asthmatic reaction in patient 6, whose responsiveness to inhaled histamine was not tested and who did not have a control test. We cannot therefore be as confident as with the cyanoacrylates that it was not acting as a non-specific provocative stimulus. This patient had, however, no respiratory symptoms before working with methyl methacrylate, he developed symptoms only after several years of using methyl methacrylate and he has experienced no further symptoms since stopping work with it. Furthermore, inhalation testing in patient 7, who had asthma, provoked no similar immediate reaction.

Cyanoacrylate and methyl methacrylate monomers can cause asthma in those who work with them. Possibly less volatile, longer chain alkyl cyanoacrylate homologues could be substituted in many adhesives, where the bond strength currently obtained is many times that required. The risk of inhalation of acrylates can be reduced by appropriate ventilation and, in the case of cyanoacrylate monomers, by maintaining relative humidity above 55%.

References